A small to mid-sized biotech with an innovative platform for the development of treatments in oncology but a limited commercial team needed support for their first commercial launch.
A small public Canadian specialty pharmaceutical company wanted to expand their footprint of commercial operations and launch into key European markets.
A major international R&D company, responsible for multiple blockbuster molecules where US rights had been out-licensed to top pharma companies, was looking to launch its first fully-owned, fully-commercialized asset into the US market.
We partnered with the commercial team to provide all commercial launch services, offering crucial global leadership that enabled the team to dynamically scale up and down to respond to changing launch timelines and to balance short- and long-term financial objectives. With a heavy emphasis on market development, we empowered the client to be fully engaged and aligned with all communities and show an in-depth understanding of market dynamics.
We helped build a European commercial capability via a comprehensive commercialization partnership, introducing a Commercial Leadership function to support the design and execution of the overall launch plan and integrate other services. We were able to scale quickly and established commercial operations, designed European launch plan, forecast and launched within three months in Germany, with a subsequent sequenced launch through Europe, despite ambiguities of COVID-19.
We provided a full virtual infrastructure that included Field Teams, MSLs, Access Teams, Marketplace and Access/Pricing Consulting, Advertising, Public Relations and Medical Communications, increasing operational efficiencies through integrated Communications teams to reduce duplication in effort across promotional channels and recruiting, training and deploying sales reps in 12 weeks, achieving an annual run rate of >$200M.